Clario announces global clinical research expert, Rod MacKenzie CMG, Ph.D., new chairman of the board of directors
PHILADELPHIA, PA – March 15, 2023 – Clario, a leading healthcare research and technology company that generates the richest clinical evidence for the clinical trials industry, today announced Rod MacKenzie CMG, Ph.D.. as their new Chairman of the Board of Directors.
“I am excited to join the team at Clario,” said Dr. MacKenzie. “The company has a strong track record in the industry of putting science at the heart of clinical research. Clario has extensive depth in cardiac safety, respiratory, imaging, and eCOA services across therapeutic areas, and is a pioneer in remote data collection. I am proud to now be a part of that journey, working with the Board and the management team to deliver innovation that supports the development of lifesaving medicines for patients”.
Dr. MacKenzie has had a distinguished career in pharmaceutical R&D research, most recently holding the position of Chief Development Officer and Executive Vice President at Pfizer Inc. He led the company’s worldwide development operations, including clinical research and development and regulatory affairs. Alongside other positions, he was previously Chair of the Board of TransCelerate – an industry-wide non-profit focused on accelerating clinical research and was a member of the Executive Committee for Clinical Trials Transformation Initiative, a public-private partnership co-founded by the FDA and Duke University to develop and drive practices that will increase the quality and efficiency of clinical trials.
“We are thrilled to have Dr. MacKenzie join us as the new Chairman of the Board of Directors,” said Chris Fikry, M.D., CEO of Clario. “Few companies can match Clario for experience and scientific expertise. Clario’s global team of science, technology and operational experts have helped deliver more than 24,000 trials, and contributed to over 500 FDA and EMEA new drug approvals that have involved more than five million patients in 120 countries. We have pioneered remote data collection so patients can participate in life-changing trials at home, and we are now leading the development and implementation of AI in clinical trial data collection and analysis. Dr. MacKenzie’s wealth of experience and knowledge across our industry will be invaluable to Clario as we take this next leap forward.”
About Clario
Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.
For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.
For more information, go to Clario.com or follow us on LinkedIn.
Media Contact:
David Malley
Director of Brand, Content Strategy, and Communications
[email protected]